AIDS

1. DAVEY CH, Dawson-Rose CS, Nokes KM, Corless IB, et al
   Sleep quality and disturbance during the COVID-19 pandemic among people with HIV globally: associations with social determinants of health.
   AIDS. 2025 Nov 28. doi: 10.1097/QAD.0000000000004417.
   

   >> Share

   
   
2. LAM JO, Fan D, Pothamsetty N, Samiezade-Yazd Z, et al
   Dementia incidence and prevalence in older adults with HIV: A 23-year retrospective cohort study.
   AIDS. 2025 Dec 2. doi: 10.1097/QAD.0000000000004421.
   

   >> Share

   
   
3. HARRICHANDPARSAD R, Lustig G, Sviridchik V, Jule Z, et al
   Cerebrospinal fluid proteomics reveals inflammatory activation in aneurysmal subarachnoid hemorrhage irrespective of HIV status.
   AIDS. 2026 Jan 15. doi: 10.1097/QAD.0000000000004445.
   

   >> Share

   
   

   
   Antimicrob Agents Chemother

4. ZOU S, Zhao X, Zhang Q, Xiao Y, et al
   Effectiveness and safety of ainuovirine plus lamivudine and tenofovir DF in virologically suppressed people living with HIV-1: the 48-week results of a multicenter, real-world study.
   Antimicrob Agents Chemother. 2026 Feb 3:e0110825. doi: 10.1128/aac.01108.
   

   >> Share

   
   

   
   Clin Infect Dis

5. SWARTWOOD NA, Cohen T, Marks SM, Hill AN, et al
   Effects of the COVID-19 pandemic on TB outcomes in the United States: a Bayesian analysis.
   Clin Infect Dis. 2025 Feb 27:ciaf092. doi: 10.1093.
   

   >> Share

   
   
6. LITTLE JS, Edelstein GE, Swank Z, Choudhary MC, et al
   Protracted SARS-CoV-2 Infection in B-cell Depleted Patients: Immunologic andiral Characteristics and Response to Dual and Extended Antiviral Therapy.
   Clin Infect Dis. 2025 Jul 16:ciaf383. doi: 10.1093.
   

   >> Share

   
   
7. SOLOVYEVA AV, Volchenkov GV, Ponomarenko OI, Kuznezova TA, et al
   Implementing a Program of Comprehensive Tuberculosis Preventive Treatment: Safety, Effectiveness, and Acceptability of Moxifloxacin or Bedaquiline Use for Contacts Exposed to Drug-Resistant Strains.
   Clin Infect Dis. 2026 Feb 3:ciaf701. doi: 10.1093.
   

   >> Share

   
   
8. SCOTT SE, Barocas JA
   Cutting federal funds for HIV testing means not Ending the HIV Epidemic.
   Clin Infect Dis. 2026 Feb 4:ciag039. doi: 10.1093.
   

   >> Share

   
   
9. BALASUBRAMANIAN R, Schnure M, Forster R, Hanage WP, et al
   The Potential Effect of Ending CDC Funding for HIV Tests: A Modeling Study in 18 States.
   Clin Infect Dis. 2026 Feb 4:ciag038. doi: 10.1093.
   

   >> Share

   
   
10. BOLDUC P
    Recognizing the Critical Role of ID Physicians in Promoting HIV Syndemic Care in Health Professions Education.
    Clin Infect Dis. 2026 Feb 5:ciag068. doi: 10.1093.
    

    >> Share

    
    

    
    HIV Med

11. SILVESTRE C, Gross A, Makinson A
    Immune non-response despite effective antiretroviral therapy in people living with HIV: A review of potential mechanisms, biomarkers and therapeutic approaches.
    HIV Med. 2026 Feb 4. doi: 10.1111/hiv.70197.
    

    >> Share

    
    
12. SIRIBELLI A, Capra N, Lolatto R, Bertoni C, et al
    Hypertriglyceridaemia and gender differences in the risk of major adverse cardiovascular events in people with HIV: A single-centre retrospective longitudinal study.
    HIV Med. 2026 Feb 2. doi: 10.1111/hiv.70203.
    

    >> Share

    
    
13. SHERIDAN R, Osei-Kuffour Ekert Y, Campbell L, Zuckerman M, et al
    Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir-based antiretroviral therapy.
    HIV Med. 2026 Feb 1. doi: 10.1111/hiv.70204.
    

    >> Share

    
    

    
    Int J Dermatol

14. SHEN A, Simonette RA, Rady PL, Tyring SK, et al
    Clinical and Molecular Perspectives on Epidermodysplasia Verruciformis.
    Int J Dermatol. 2026 Feb 6. doi: 10.1111/ijd.70295.
    

    >> Share

    
    

    
    J Acquir Immune Defic Syndr

15. RIPAMONTI E, Ma Q, Umlauf A, Letendre S, et al
    Neurocognitive performance and depressive mood in people with HIV: The role of prescription opioids use.
    J Acquir Immune Defic Syndr. 2026 Feb 2. doi: 10.1097/QAI.0000000000003841.
    

    >> Share

    
    
16. BUZIBYE A, Hoke A, Bollinger RC, Omali D, et al
    Letter to the editor: Mitochondrial DNA patterns among individuals living with HIV-1 on dolutegravir with hyperglycemia.
    J Acquir Immune Defic Syndr. 2026 Feb 2. doi: 10.1097/QAI.0000000000003838.
    

    >> Share

    
    
17. EKII OA, Kibengo FM, Samson O, Kizito K, et al
    High HIV incidence among HIV infected BUT undetected individuals seeking HIV voluntary counselling and testing services in the greater Masaka Region in Uganda.
    J Acquir Immune Defic Syndr. 2026 Feb 2. doi: 10.1097/QAI.0000000000003843.
    

    >> Share

    
    
18. JOHNSON K, Billock R, Hallmark C, France AM, et al
    National HIV Molecular Cluster Detection Supports Local Cluster Detection.
    J Acquir Immune Defic Syndr. 2026 Feb 2. doi: 10.1097/QAI.0000000000003839.
    

    >> Share

    
    
19. KALICHMAN SC, Kalichman MO, Holt J, Stearns C, et al
    Dose Determination Trial for Evidence-Based Behavioral Counseling to Improve.
    J Acquir Immune Defic Syndr. 2026 Feb 2. doi: 10.1097/QAI.0000000000003842.
    

    >> Share

    
    
20. REIS K, Lu X, Seepamore B, Wolf A, et al
    Characterizing the dual burden of stigma in people with multidrug-resistant tuberculosis (MDR-TB) and HIV co-infection in South Africa: A mixed methods, prospective cohort study.
    J Acquir Immune Defic Syndr. 2026 Feb 2. doi: 10.1097/QAI.0000000000003835.
    

    >> Share

    
    
21. VASQUEZ E, Kuniholm MH, Appleton AA, Noor MI, et al
    Cardiovascular Disease Risk and Falls in Men and Women Living with and Without HIV in MACS/WIHS Combined Cohort Study.
    J Acquir Immune Defic Syndr. 2026 Feb 2. doi: 10.1097/QAI.0000000000003844.
    

    >> Share

    
    
22. SHI F, Xia H, Li X, Olatosi B, et al
    Long COVID Between People With and Without HIV: a Statewide Cohort Analysis.
    J Acquir Immune Defic Syndr. 2026 Feb 4. doi: 10.1097/QAI.0000000000003840.
    

    >> Share

    
    
23. SILVA MST, Torres TS, Teixeira SLM, Jalil EM, et al
    HIV testing, incidence, and transmitted drug resistance among young cis men and non-binary persons who have sex with men.
    J Acquir Immune Defic Syndr. 2026 Feb 5. doi: 10.1097/QAI.0000000000003848.
    

    >> Share

    
    
24. MCCORMACK S, Dunn D, Kusemererwa S, Munseri P, et al
    A comparison of F/TAF and F/TDF as HIV pre-exposure prophylaxis in a predominantly cisgender women population in East and South Africa: a randomised, factorial, non-inferiority trial.
    J Acquir Immune Defic Syndr. 2026 Feb 6. doi: 10.1097/QAI.0000000000003845.
    

    >> Share

    
    

    
    J Infect Dis

25. KHETAN P, Patel K, Yu W, Szewczyk J, et al
    Dynamics of Intact and Defective HIV-1 Proviruses during Decades of Suppressive Antiretroviral Treatment in Young Adults with Perinatal HIV-1.
    J Infect Dis. 2026 Jan 30:jiag045. doi: 10.1093.
    

    >> Share

    
    
26. GIANELLA S, Lauring A, Paredes R, Croda J, et al
    Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV Research.
    J Infect Dis. 2026 Feb 2:jiag063. doi: 10.1093.
    

    >> Share

    
    
27. DONENBERG GR, Eisinger RW
    Future Directions for NIH HIV Research: A Look Ahead to 2026.
    J Infect Dis. 2026 Feb 2:jiag062. doi: 10.1093.
    

    >> Share

    
    
28. ENDRIAS K, Sonawane S, Easley KA, Ukhueduan B, et al
    Limited sex-based differences in viral outcomes of ART-treated SIV/SHIV infection.
    J Infect Dis. 2026 Feb 3:jiag064. doi: 10.1093.
    

    >> Share

    
    
29. DA SILVA FC, Yokoya K, Hussain R, Kamuyu G, et al
    Influence of Chlamydia trachomatis sequence variation on Pgp3 antigenicity.
    J Infect Dis. 2026 Feb 4:jiag067. doi: 10.1093.
    

    >> Share

    
    
30. AWADA A, Tough RH, Fellay J, McLaren PJ, et al
    Multi-ancestry GWAS identifies variants in a zinc finger gene cluster as novel regulators of HIV control.
    J Infect Dis. 2026 Feb 5:jiag072. doi: 10.1093.
    

    >> Share

    
    
31. ROUTY JP, Isnard S
    Increasing handgrip strength to combat frailty in HIV: Linking immune exhaustion to a bone health indicator.
    J Infect Dis. 2026 Feb 6:jiag082. doi: 10.1093.
    

    >> Share

    
    
32. ZHANG X
    When PD-1 Meets Plaque: Making CD8 Senescence Signals Clinically Actionable in Treated HIV.
    J Infect Dis. 2026 Feb 5:jiag081. doi: 10.1093.
    

    >> Share

    
    
33. FREEMAN ML, Fitzgerald W, Clagett BM, O'Hare KA, et al
    Frailty in People with HIV is Linked to Inflammation, Bone Health, and T cell Exhaustion.
    J Infect Dis. 2026 Feb 6:jiag046. doi: 10.1093.
    

    >> Share

    
    

    
    Lancet Infect Dis

34. HEYSELL SK, Mpagama SG, Nuwagira E, Said B, et al
    Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 x 2 factorial, superiority trial.
    Lancet Infect Dis. 2026 Jan 28:S1473-3099(25)00747.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

35. CHANDASANA H, Buchanan AM, Henegar CA, McKenna M, et al
    Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance.
    Pediatr Infect Dis J. 2026 Feb 4. doi: 10.1097/INF.0000000000005158.
    

    >> Share

    
    

    
    Pediatrics

36. HAQUE T, Abdah S, Spyropoulos S, Clouser K, et al
    Not Just Depression: A Delayed Diagnosis of HIV Dementia in an Adolescent Boy.
    Pediatrics. 2026 Feb 3:e2025071517. doi: 10.1542/peds.2025-071517.
    

    >> Share

    
    

    
    PLoS Biol

37. SALADINO N, Leavitt E, Wong HT, Ji JH, et al
    DNA damage induced by HIV-1 Vpr triggers epigenetic remodeling and transcriptional programs to enhance virus transcription and latency reactivation.
    PLoS Biol. 2026;24:e3003621.
    

    >> Share

    
    

    
    PLoS One

38. NATTEY C, Maskew M, Jinga N, Rossouw L, et al
    The impact of expanded access to antiretroviral treatment on engagement in HIV care and viral suppression among pregnant women living with HIV in South Africa.
    PLoS One. 2026;21:e0314182.
    

    >> Share

    
    
39. FEYISSA BB, Sisay A, Davids EL, Yalew A, et al
    Virological failure and risk factors among people living with HIV taking second-line ART in Addis Ababa, Ethiopia.
    PLoS One. 2026;21:e0330581.
    

    >> Share

    
    
40. ZAKUMUMPA H, Ssegujja E, Kyomuhendo M, Maritim B, et al
    The sustainability of public health programs following donor transition: A comparative case study of HIV services and maternal and newborn care in Uganda.
    PLoS One. 2026;21:e0341328.
    

    >> Share

    
    
41. WANG H, Li X, Shangguan L
    Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database.
    PLoS One. 2026;21:e0341855.
    

    >> Share

    
    
42. OJA D, Jiang W, Richardson BA, Badia J, et al
    Psychosocial correlates of adherence self-efficacy and HIV viral suppression among adolescents and young adults in Western Kenya.
    PLoS One. 2026;21:e0341269.
    

    >> Share

    
    
43. STANGL AL, Bryan C, Barre I, Ramskin L, et al
    The influence of stigma on PrEP uptake among adolescent girls and young women in Johannesburg, South Africa and Mwanza, Tanzania: Qualitative findings from the EMPOWER study.
    PLoS One. 2026;21:e0339380.
    

    >> Share

    
    
44. OKELLO W, Mugerwa Ssentongo S, Oryokot B, Bakashaba B, et al
    Determinants of return to HIV treatment after interruption on ART among HIV positive clients in Katakwi District, Uganda.
    PLoS One. 2026;21:e0337637.
    

    >> Share

    
    
45. MSOKA P, Swai I, Ngowi K, Reis R, et al
    Implementation of point of care HIV viral load monitoring for people living with HIV in low- and middle-income countries: A systematic review on implementation research outcomes.
    PLoS One. 2026;21:e0313802.
    

    >> Share

    
    
46. HLOPHE LD, Nyasulu PS, Shumba CS
    A mobile game to promote ART adherence among adolescents living with HIV in Eswatini: Development and prototype testing of "The Conqueror".
    PLoS One. 2026;21:e0321907.
    

    >> Share

    
    
47. WANG L, Lu L, Tu Z, Qiu L, et al
    Spatiotemporal aggregation and population distribution characteristics of HIV/AIDS in Nanchang city: A monitoring analysis from 2012-2021.
    PLoS One. 2026;21:e0342375.
    

    >> Share

    
    
48. GALICIA P, Garcia de Yebenes MJ, Pascau C, Cuadros Gonzalez J, et al
    Barriers and facilitators to the diagnosis of HIV and other STIs in primary care within publicly funded healthcare systems: A systematic review of qualitative studies.
    PLoS One. 2026;21:e0341919.
    

    >> Share

    
    
49. MUHUMUZA R, Ndekezi D, Nagawa R, Awino E, et al
    Navigating HIV self-testing: Concerns among adolescents and young people aged 15-24 years in Uganda. An exploratory qualitative study.
    PLoS One. 2026;21:e0330000.
    

    >> Share

    
    
50. LANGA JC, Moon TD, Sacarlal J, Sidat M, et al
    Challenges in diagnosing cryptococcosis among HIV-infected patients in southern Mozambique and opportunities for intervention in contexts of limited resources: A pre-implementation study.
    PLoS One. 2026;21:e0340217.
    

    >> Share

    
    
51. VO-QUANG E, Guingane AN, Perieres L, Ndow G, et al
    Towards triple elimination of HIV, syphilis and HBV mother-to-child transmission: Protocol of a simplified and integrated strategy in Burkina Faso and The Gambia: Protocol for the phase 1 of the TRI-MOM project.
    PLoS One. 2026;21:e0322670.
    

    >> Share

    
    
52. SIDDIQI KA, Canidate SS, Liu Y, Kriegel LS, et al
    HIV pre-exposure prophylaxis practices in Florida, USA: Clinicians' perceptions of initiation, risk identification, barriers, and facilitators.
    PLoS One. 2026;21:e0319139.
    

    >> Share

    
    

    
    PLoS Pathog

53. LARIOS R, Hossain MB, Brown R, Jeyachandran AV, et al
    B Cell Receptor's function in virus entry: Anti-SARS-CoV-2 B cell receptors can mediate viral entry in an ACE2-independent mechanism.
    PLoS Pathog. 2026;22:e1013946.
    

    >> Share

    
    
54. KUMAR N, Ma Z, Long F, Bonam SR, et al
    Mechanistic insights and in vivo HIV suppression by the BRD4-targeting small molecule ZL0580.
    PLoS Pathog. 2026;22:e1013449.
    

    >> Share

    
    
55. MARTINEZ-MARTINEZ YB, Huante MB, Naqvi KF, Shah MN, et al
    HIV impairs and exploits pulmonary Th17 and Th22 cell-mediated immune responses to Mycobacterium tuberculosis.
    PLoS Pathog. 2026;22:e1013897.
    

    >> Share

    
    
56. ZHOU C, He H, Zhang Y, Liu X, et al
    YAP Inhibits HIV-1 transcription and promotes HIV-1 latency by regulating E3 ubiquitin ligase UHRF1 mediated tat degradation.
    PLoS Pathog. 2026;22:e1013906.
    

    >> Share

    
    

    
    Science

57. BANNARD O, Howarth MR
    A double helix twist in HIV vaccine design.
    Science. 2026;391:553-554.
    

    >> Share

    
    
58. ROMANOV A, Knappe GA, Ronsard L, Cottrell CA, et al
    DNA origami vaccines program antigen-focused germinal centers.
    Science. 2026;391:eadx6291.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share